Alan Bash
Directeur Général chez Zielbio, Inc.
Profil
Alan S.
Bash is currently the Chief Executive Officer & Director at Zielbio, Inc. Prior to this, he was the President, Chief Executive Officer & Director at Checkmate Pharmaceuticals, Inc. in 2022.
He also worked as a Senior Vice President-Commercial Model Innovation at Bristol Myers Squibb Co. Mr. Bash completed his undergraduate degree at Georgetown University and earned an MBA from Columbia Business School.
Postes actifs de Alan Bash
| Sociétés | Poste | Début |
|---|---|---|
Zielbio, Inc.
 Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA. | Directeur Général | 03/01/2023 |
Anciens postes connus de Alan Bash
| Sociétés | Poste | Fin |
|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
| CHECKMATE PHARMACEUTICALS, INC. | Directeur Général | - |
Formation de Alan Bash
| Georgetown University | Undergraduate Degree |
| Columbia Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| Entreprise privées | 2 |
|---|---|
Checkmate Pharmaceuticals, Inc.
 Checkmate Pharmaceuticals, Inc. BiotechnologyHealth Technology Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing proprietary technology to harness the power of the immune system to combat cancer. The firm's product candidate, vidutolimod is a differentiated TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body's innate immune system to attack tumors in combination with other therapies. The company was founded by Arthur M. Krieg and Chuck Yo in July 2015 and is headquartered in Cambridge, MA. | Health Technology |
Zielbio, Inc.
Zielbio, Inc. Medical SpecialtiesHealth Technology Zielbio, Inc. develops a technology for identification of cancerous diseases. Its technology identifies high-value biomarkers of disease as well as companion targeting peptides capable of delivery of therapeutic payloads and as imaging agents. The company was founded by Kimberly A. Kelly, Gregory B. Fralish, Todd William Bauer in 2010 and is headquartered in Charlottesville, VA. | Health Technology |